Allogene Therapeutics (ALLO) Non-cash Items (2018 - 2019)
Allogene Therapeutics' (ALLO) quarterly Non-cash Items came in at $3.7 million in Q1 2019, down 97.34% quarter-over-quarter from $139.0 million in Q4 2018.
Allogene Therapeutics (ALLO) Non-cash Items (2018 - 2019) Analysis & Trends
Allogene Therapeutics has disclosed Non-cash Items across 2 years of filings, most recently posting $3.7 million for Q1 2019.
- Non-cash Items for Q1 2019 came in at $3.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2019 was $3.7 million (changed N/A YoY), and the FY2018 annual result was $139.0 million, changed N/A from the prior year.
- Non-cash Items came in at $3.7 million for Q1 2019 at Allogene Therapeutics, down from $139.0 million in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $139.0 million in Q4 2018 to a low of $2.7 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Allogene Therapeutics | 482.98 Mn | 482.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 3.69 Mn |
| Mar 31, 2019 | 3.69 Mn |
| Dec 31, 2018 | 139.00 Mn |
| Dec 31, 2018 | 139.00 Mn |
| Sep 30, 2018 | 2.66 Mn |
| Sep 30, 2018 | 2.66 Mn |